KDR and adrenal cortex carcinoma: The high expression of the FGFR1 and 4 in ACCs is a promising first indication that FGFR inhibitors like ponatinib (pan-FGFR, PDGFR, SRC, RET, KIT and FLT1 inhibitor) (24), lenvatinib (VEGFR, pan-FGFR, PDGFRα, KIT and RET inhibitor) (23), rogaratinib (selective FGFR 4 inhibitor) (65) or others may have better therapeutic efficacy than the other RTK inhibitors that have been tested until now for the treatment of ACC.